Laminin chains: diagnostic and therapeutic use

Abstract

The instant invention provides for the identification, diagnosis, monitoring, and treatment of invasive cells using the laminin 5 gamma-2 chain protein or nucleic acid sequence, or antibodies thereto.

We claim:  
     
         1 . A method for detecting kalinin/laminin 5 expression in cells and tissue comprising detecting a signal from the tissue assayed, such signal resulting from specifically hybridizing the tissue with an effective amount of a nucleic acid probe, which probe contains a sense or antisense portion of the kalinin/laminin 5 gamma-2 chain nucleic acid sequence.  
     
     
         2 . The method of  claim 1  where the nucleic acid probe is DNA.  
     
     
         3 . The method of  claim 1  where the nucleic acid probe is RNA.  
     
     
         4 . The method of  claim 1  where the nucleic acid probe is radiolabelled, enzyme labelled, chemiluminescent labelled, avidin or biotin labelled.  
     
     
         5 . The method of  claim 1  where the nucleic acid probe derived from human kalinin/laminin 5 gamma-2 chain nucleic acid sequence.  
     
     
         6 . The method of  claim 1  where the nucleic acid probe is incorporated into an extrachromasomal self-replicating vector.  
     
     
         7 . The method of  claim 1  where the nucleic acid probe is incorporated into a viral vector.  
     
     
         8 . The method of  claim 1  where the nucleic acid probe is linear.  
     
     
         9 . The method of  claim 1  where the nucleic acid probe is circularized.  
     
     
         10 . The method of  claim 1  where the nucleic acid probe contains modified nucleotides.  
     
     
         11 . A method for detecting the presence of invasive cells in tissue comprising detecting a signal from the tissue assayed, such signal resulting from specifically hybridizing the tissue with an effective amount of a nucleic acid probe, which probe contains a sense or antisense portion of kalinin/laminin 5 gamma-2 chain nucleic acid sequence.  
     
     
         12 . The method of  claim 11  where the nucleic acid probe is DNA.  
     
     
         13 . The method of  claim 11  where the nucleic acid probe is RNA.  
     
     
         14 . The method of  claim 11  where the nucleic acid probe is radiolabelled, enzyme labelled, chemiluminescent labelled, avidin or biotin labelled.  
     
     
         15 . The method of  claim 11  where the nucleic acid probe derived from human kalinin/laminin 5 gamma-2 chain nucleic acid sequence.  
     
     
         16 . The method of  claim 11  where the nucleic acid probe is incorporated into an extrachromasomal self-replicating vector.  
     
     
         17 . The method of  claim 11  where the nucleic acid probe is incorporated into a viral vector.  
     
     
         18 . The method of  claim 11  where the nucleic acid probe is linear.  
     
     
         19 . The method of  claim 11  where the nucleic acid probe is circularized.  
     
     
         20 . The method of  claim 11  where the nucleic acid probe contains modified nucleotides.  
     
     
         21 . A method for monitoring the presence of invasive cells in tissue comprising detecting a signal or absence of signal from the tissue assayed, such signal resulting from specifically hybridizing the tissue with an effective amount of a nucleic acid probe, which probe contains a sense or antisense portion of kalinin/laminin 5 gamma-2 chain nucleic acid sequence.  
     
     
         22 . The method of  claim 21  where the nucleic acid probe is DNA.  
     
     
         23 . The method of  claim 21  where the nucleic acid probe is RNA.  
     
     
         24 . The method of  claim 21  where the nucleic acid probe is radiolabelled, enzyme labelled, cheruluminescent labelled, avidin or biotin labelled.  
     
     
         25 . The method of  claim 21  where the nucleic acid probe derived from human kalinin/laminin 5 gamma-2 chain nucleic acid sequence.  
     
     
         26 . The method of  claim 21  where the nucleic acid probe is incorporated into an extrachromasomal self-replicating vector.  
     
     
         27 . The method of  claim 21  where the nucleic acid probe is incorporated into a viral vector.  
     
     
         28 . The method of  claim 21  where the nucleic acid probe is linear.  
     
     
         29 . The method of  claim 21  where the nucleic acid probe is circularized.  
     
     
         30 . The method of  claim 21  where the nucleic acid probe contains modified nucleotides.  
     
     
         31 . A method for detecting kalinin/laminin 5 expression in cells and tissue comprising detecting a signal from assayed tissue, such signal resulting from contacting tissue with an effective amount of a labeled probe, which probe contains an antibody immunoreactive with a portion of kalinin/laminin 5 gamma-2 chain protein.  
     
     
         32 . A method for detecting invasive cells in tissue comprising detecting a signal from assayed tissue, such signal resulting from contacting tissue with an effective amount of a labeled probe, which probe contains an antibody immunoreactive with a portion of kalinin/laminin 5 gamma-2 chain protein.  
     
     
         33 . A method for monitoring invasive cells in malignant tissue comprising detecting a signal from assayed malignant tissue, such signal resulting from contacting tissue with an effective amount of a labeled probe, which probe contains an antibody immunoreactive with a portion of kalinin/laminin 5 gamma-2 chain protein.